InnoFeed28 October 2021
Probiotika27 October 2021
Definition and optimisation of a mixture of prebiotics (2 selected plant extracts) /probiotics to be used in the treatment of IBS and AD, with confirmation of the beneficial properties (antioxidant, prebiotic, anti-inflammatory) with main focus on the anti-inflammatory effect, with evaluation of stability. Acquisition of the clinical trial with microbiome analysis, with collection of sufficient data for scientific publication and patenting.
The SCIDA project is oriented towards the development and validation of new pre- and probiotic products for the prevention and treatment of IBS and AD, which are then clinically tested by analysing the intestinal microbiome of volunteers before and after treatment with the product, using Illumina technology. The mixtures of probiotics and prebiotics (botanicals) are formulated in different ways (sachets and capsules) to assess their stability over time and set up industrialisation
Do you want to know what we can do for you?